Literature DB >> 27054127

Periostin - A Novel Systemic Biomarker for Eosinophilic Airway Inflammation: A Case Control Study.

Viswanathan Emprm1, M G Rajanandh2, A D Nageswari3.   

Abstract

INTRODUCTION: Chronic airway inflammation and remodelling are fundamental features of asthma. The molecular phenotypes in asthma are Th2 high and Th2 low. Serum periostin is a biomarker which aid in understanding Th2 high eosinophilic asthma. AIM: The present study aimed to identify whether or not serum periostin is a systemic biomarker for eosinophilic airway inflammation in asthmatics.
MATERIALS AND METHODS: The study was designed as a prospective, case control study. Patients who presented with consistent symptoms of asthma and confirmed by spirometry with reversibility were the cases. The controls were healthy subjects who had no history of lung disease with normal lung function. The sputum and blood samples were collected from both the groups. Sputum eosinophils, Absolute Eosinophil Counts (AEC) and serum periostin levels were compared between the groups.
RESULTS: The study comprised of 101 participants in which 30 were controls and 71 were cases. In the study group, mean post FEV1 was 64.45. There was a positive correlation of sputum eosinophils with severity of obstruction. The ROC curve analysis showed the cut-off value of 24.556 for serum periostin with the p-value of <0.001. As the severity of obstruction increased, the serum periostin levels were also found to be increased. Serum periostin had a sensitivity and specificity of 97.18% and 86.67% with a diagnostic accuracy of 94.06%.
CONCLUSION: Serum periostin appears to be a more sensitive tool for detection of airflow limitation in asthmatic patients with a Th2 high eosinophilic phenotype when compared to AEC and sputum eosinophils.

Entities:  

Keywords:  Absolute eosinophil counts; Airway remodeling; Spirometry

Year:  2016        PMID: 27054127      PMCID: PMC4800558          DOI: 10.7860/JCDR/2016/14553.7166

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  17 in total

Review 1.  Asthma: defining of the persistent adult phenotypes.

Authors:  Sally E Wenzel
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

2.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

3.  What is an "eosinophilic phenotype" of asthma?

Authors:  Parameswaran Nair
Journal:  J Allergy Clin Immunol       Date:  2013-05-31       Impact factor: 10.793

Review 4.  Serum periostin: a novel biomarker for asthma management.

Authors:  Hisako Matsumoto
Journal:  Allergol Int       Date:  2014-04-25       Impact factor: 5.836

5.  Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood.

Authors:  E Pizzichini; M M Pizzichini; A Efthimiadis; J Dolovich; F E Hargreave
Journal:  J Allergy Clin Immunol       Date:  1997-04       Impact factor: 10.793

6.  Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects.

Authors:  Annette T Hastie; Wendy C Moore; Huashi Li; Brian M Rector; Victor E Ortega; Rodolfo M Pascual; Stephen P Peters; Deborah A Meyers; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2013-05-21       Impact factor: 10.793

Review 7.  Which biomarkers are effective for identifying Th2-driven inflammation in asthma?

Authors:  Zuzana Diamant; Ellen Tufvesson; Leif Bjermer
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

8.  Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

Authors:  Go Takayama; Kazuhiko Arima; Taisuke Kanaji; Shuji Toda; Hiroyuki Tanaka; Shunsuke Shoji; Andrew N J McKenzie; Hiroichi Nagai; Takao Hotokebuchi; Kenji Izuhara
Journal:  J Allergy Clin Immunol       Date:  2006-04-27       Impact factor: 10.793

9.  Lebrikizumab in the personalized management of asthma.

Authors:  Neil C Thomson; Manish Patel; Andrew D Smith
Journal:  Biologics       Date:  2012-09-14

Review 10.  Dupilumab: a novel treatment for asthma.

Authors:  Alessandro Vatrella; Immacolata Fabozzi; Cecilia Calabrese; Rosario Maselli; Girolamo Pelaia
Journal:  J Asthma Allergy       Date:  2014-09-04
View more
  2 in total

Review 1.  Fibroblast-to-myofibroblast transition in bronchial asthma.

Authors:  Marta Michalik; Katarzyna Wójcik-Pszczoła; Milena Paw; Dawid Wnuk; Paulina Koczurkiewicz; Marek Sanak; Elżbieta Pękala; Zbigniew Madeja
Journal:  Cell Mol Life Sci       Date:  2018-08-12       Impact factor: 9.261

2.  Soluble CD93 in allergic asthma.

Authors:  Hye Jung Park; Eun-Yi Oh; Hee-Jae Han; Kyung Hee Park; Kyoung-Yong Jeong; Jung-Won Park; Jae-Hyun Lee
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.